Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104388 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
A Phase 2 study of Corneal Epithelial Disorders, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 17
- Study locations
NCT02104388: Completed Phase 2 study of Corneal Epithelial Disorders, sponsored by Senju Pharmaceutical Co..
NCT02104388 is a Phase 2 study of Corneal Epithelial Disorders that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 69 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02104388, a Phase 2 study of Corneal Epithelial Disorders, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Primary Outcome
A patient will be considered a success for clearing of corneal fluorescein staining if their fluorescein staining has disappeared.
Conditions Studied
Interventions
- DRUG SJP-0035 Ophthalmic Solution
- DRUG Vehicle of SJP-0035 Ophthalmic Solution
Study Locations (17)
California
- Senju Investigational Site - Glendale
- Senju Investigational Site - Glendora
- Senju Investigational Site - Huntington Beach
- Senju Investigational Site - Lancaster
- Senju Investigational Site - Newport Beach
- Senju Investigational Site - Pasadena
- Senju Investigational Site - Petaluma
- Senju Investigational Site - Santa Maria
Arkansas
- Senju Investigational Site - Little Rock
Illinois
- Senju Investigational Site - Hoffman Estates
Kentucky
- Senju Investigational site - Edgewood
Missouri
- Senju Investigational Site - Kansas City
New Jersey
- Senju Investigational Site - Palisades Park
New York
- Senju Investiational Site - Rochester
North Carolina
- Senju Investigational Site - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-04-08 |
| Est. Completion | 2015-08-04 |
| Phase | Phase 2 |
What the finished NCT02104388 record still lists
NCT02104388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Corneal Epithelial Disorders appearing as the primary indexed condition, and to 2 interventions - of which SJP-0035 Ophthalmic Solution is the first listed.
NCT02104388 lists 17 locations in 10 states (California, Arkansas, Illinois).
Frequently Asked Questions
What is clinical trial NCT02104388 about?
NCT02104388 is a clinical study titled "Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders". The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
What is the current status of trial NCT02104388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2014-04-08. Estimated completion is 2015-08-04.
What conditions does trial NCT02104388 study?
This clinical trial studies the following conditions: Corneal Epithelial Disorders.
What interventions are being tested in trial NCT02104388?
The interventions under investigation include: SJP-0035 Ophthalmic Solution (DRUG), Vehicle of SJP-0035 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02104388?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02104388 being conducted?
This trial has 17 study locations across Arkansas, California, Illinois, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Epithelial Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02104388's enrollment target sits among peer trials
69 965th of 2000 higher than 1,034 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI